NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Was not the case i the external comparator trials. Critics of the trial documented the external comparator trial profiles in their peer-reviewed article in The Neuro-Oncology Journa. Read the publication, it outlines the comparator trials did not get the benefit of the healthiest GBM patient sample that the NWBO screener created

The authors of the Neuro-Oncology Journal are wrong. If the GBM patients were on the average healthier than the patients in the comparator trial, the 131 unmethylated GBM treatment patients (about 40% of the DCVax-L trial) would have displayed an mOS that would have been significantly longer than the mOS of the unmethylated GBM patients in the comparator trials. Instead, the mOS of the unmethylated treatment patients was 16.9 months, a mere 0.3 months longer than the mOS of the unmethylated GBM patients of the ECAs. I have posted this point several times but never received an answer that nullifies my argument.

I trust the 70 authors of the JAMA publication far more than the 2 authors of the non peer reviewed Neuro-Oncology article.